Seaport Therapeutics
Seaport Therapeutics is dedicated to advancing novel antidepressants and anxiolytics based on clinically validated mechanisms through their Glyph™ platform. They focus on developing first and best-in-class medicines for neuropsychiatric disorders, leveraging their proprietary platform to overcome limitations of previous drugs, such as poor bioavailability and hepatotoxicity. Their mission is to help people living with neuropsychiatric disorders by creating innovative therapies.
Industries
Nr. of Employees
small (1-50)
Seaport Therapeutics
Products
SPT-300 (allopregnanolone prodrug)
Oral prodrug of allopregnanolone designed to enable lymphatic absorption, increase oral bioavailability, and deliver therapeutically relevant plasma exposures with CNS pharmacodynamic effects in early clinical studies.
SPT-320 (agomelatine prodrug)
Oral prodrug of agomelatine engineered to increase lymphatic uptake, reduce first-pass hepatic metabolism, and produce therapeutically relevant agomelatine exposures with lower hepatic dosing burden in preclinical models.
SPT-348 (non‑hallucinogenic neuroplastogen, discovery)
Discovery‑stage program applying biomimetic glyceride prodrug design to non‑hallucinogenic neuroplasticity‑promoting molecules aimed at improving pharmacokinetics and tolerability for mood and neuropsychiatric disorders.
Conference posters and peer‑reviewed papers
Selected scientific posters and peer‑reviewed publications describing platform design, preclinical ADME, PK/PD translation, and clinical trial analyses.
SPT-300 (allopregnanolone prodrug)
Oral prodrug of allopregnanolone designed to enable lymphatic absorption, increase oral bioavailability, and deliver therapeutically relevant plasma exposures with CNS pharmacodynamic effects in early clinical studies.
SPT-320 (agomelatine prodrug)
Oral prodrug of agomelatine engineered to increase lymphatic uptake, reduce first-pass hepatic metabolism, and produce therapeutically relevant agomelatine exposures with lower hepatic dosing burden in preclinical models.
SPT-348 (non‑hallucinogenic neuroplastogen, discovery)
Discovery‑stage program applying biomimetic glyceride prodrug design to non‑hallucinogenic neuroplasticity‑promoting molecules aimed at improving pharmacokinetics and tolerability for mood and neuropsychiatric disorders.
Conference posters and peer‑reviewed papers
Selected scientific posters and peer‑reviewed publications describing platform design, preclinical ADME, PK/PD translation, and clinical trial analyses.
Services
Lymphatic-targeted oral prodrug development and translational R&D
End‑to‑end discovery and preclinical development of oral prodrugs that promote intestinal lymphatic absorption to improve oral bioavailability and reduce hepatic exposure, including medicinal chemistry, in vitro/in vivo ADME, and preclinical PK/PD work.
Clinical development and early‑phase trial execution (SAD/MAD/food effect)
Design and execution of early-phase clinical studies with integrated safety, PK and PD assessments tailored for CNS-active prodrugs.
Lymphatic-targeted oral prodrug development and translational R&D
End‑to‑end discovery and preclinical development of oral prodrugs that promote intestinal lymphatic absorption to improve oral bioavailability and reduce hepatic exposure, including medicinal chemistry, in vitro/in vivo ADME, and preclinical PK/PD work.
Clinical development and early‑phase trial execution (SAD/MAD/food effect)
Design and execution of early-phase clinical studies with integrated safety, PK and PD assessments tailored for CNS-active prodrugs.
Expertise Areas
- Neuropsychiatric therapeutics (MDD, GAD and mood disorders)
- Prodrug design and lipid conjugation
- Translational pharmacokinetics and ADME
- Preclinical to first‑in‑human translation
Key Technologies
- Biomimetic glyceride prodrugs
- Lipid conjugation/linker chemistry
- Lymphatic-targeted oral delivery
- Lymph-cannulated animal models